- Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
-
Date lodged: Thursday, 18 August 2022
-
Current Status:
Answered by Humza Yousaf on 20 September 2022
To ask the Scottish Government whether all people who were on the former shielding list are eligible for anti-viral medication for the treatment of COVID-19.
Answer
I refer the member to the answer to question S6W-09978 on 24 August 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.
- Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
-
Date lodged: Thursday, 18 August 2022
-
Current Status:
Answered by Humza Yousaf on 20 September 2022
To ask the Scottish Government whether any NHS board is failing to meet national stroke service standards.
Answer
The Scottish Stroke Improvement Programme report, published on 28 June, includes data from the Scottish Stroke Care Audit (SSCA). The SSCA measures quality of care of stroke services in each acute hospital, grouped by NHS board against the Scottish Stroke Care Standards.
- Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
-
Date lodged: Thursday, 18 August 2022
-
Current Status:
Answered by Humza Yousaf on 20 September 2022
To ask the Scottish Government whether vulnerable people will have access to the drug, Evusheld, to protect against COVID-19 and, if so, when this will become available.
Answer
I refer the member to the answer to question S6W-10433 on 20 September 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.
- Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
-
Date lodged: Thursday, 18 August 2022
-
Current Status:
Answered by Humza Yousaf on 20 September 2022
To ask the Scottish Government what its response is regarding any impact on Scotland of reports that the UK Government will not procure the COVID-19 drug, Evusheld, to treat vulnerable patients this winter.
Answer
Throughout the pandemic, a UK-wide approach to the procurement of therapeutics has been vital to allow the UK to have the buying power to secure significant numbers of therapeutics in a competitive global market. This approach has ensured patients across the UK have had equal access to safe and effective medicines.
Evusheld ® was developed and tested before the emergence of the Omicron variant, and the UK Medicines and Healthcare products Regulatory Agency’s (MHRA) conditional marketing authorisation outlined some remaining questions, including how effective Evusheld ® is against Omicron and the duration of its effect against current circulating variants. As a result, there is currently no established supply arrangement for Evusheld ® in the UK. The UK Health Security Agency (UKHSA) is carrying out further testing on the effectiveness of Evusheld ® against the Omicron variants which involve “live virus” tests taking place in the lab (“in vitro”). These tests are important because they provide certainty of the effectiveness of Evusheld ® against circulating variants and avoid the risk of introducing new variants through viral mutations.
The Scottish Government continues to closely monitor the outcome of further research to ensure that any decisions to make Evusheld ® available to patients in Scotland in the future are based on the best available evidence.
- Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
-
Date lodged: Thursday, 18 August 2022
-
Current Status:
Answered by Humza Yousaf on 20 September 2022
To ask the Scottish Government what action is being taken by any NHS boards that are currently not meeting the national stroke service standard to achieve the necessary standards of service.
Answer
The Scottish Stroke Improvement Programme (SSIP) Lead conducts a review process and meets with all NHS boards to understand the provision of stroke services and create a local action plan to improve performance where needed.
We recognise that the Scottish Stroke Care Standards are challenging for the service and expect Stroke Managed Clinical Networks and Health Boards to work together to drive forward quality improvement programmes of work to achieve these.
- Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
-
Date lodged: Thursday, 18 August 2022
-
Current Status:
Answered by Humza Yousaf on 20 September 2022
To ask the Scottish Government how it plans to restore NHS stroke care, specifically the national stroke care bundle, to its pre-COVID-19 pandemic quality service standard.
Answer
I refer the member to the answer to question S6W-10404 on 20 September 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers
- Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
-
Date lodged: Monday, 22 August 2022
-
Current Status:
Answered by Humza Yousaf on 20 September 2022
To ask the Scottish Government, in light of reports that the Department of Health and Social Care has asked NICE to conduct an appraisal of remdesivir, tocilizumab, casirivimab and imdevimab, baricitinib, sotrovimab, molnupiravir, nirmatrelvir and ritonavir, and tixagevimab and cilgavimab for treating people with coronavirus disease 2019 (COVID-19) in the NHS in England, whether it will refer any of these currently available COVID-19 treatments to the Scottish Medicines Consortium.
Answer
As part of the Scottish Medicines Consortium’s (SMC) continuing role in the UK-wide multi-agency RAPID C-19 initiative, the collaborative partnership between the SMC and the National Institute for Health and Care Excellence (NICE) will extend to the multiple technology assessment (MTA) of the range of therapeutics for the treatment of COVID-19; therefore, a separate assessment of these medicines by the SMC will not be required.
- Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
-
Date lodged: Monday, 22 August 2022
-
Current Status:
Answered by Humza Yousaf on 20 September 2022
To ask the Scottish Government when NHS Scotland will publish a winter resilience plan.
Answer
My intention is to update Parliament with our Winter Resilience plans and publish our Winter Resilience Overview, covering both the NHS and Social Care, early next month, subject to discussions at Parliamentary Bureau. Caroline Lamb, CEO of NHS Scotland has also already written to NHS Boards and Integration Authorities regarding winter resilience plans at a national level and setting out clear expectations for local resilience and response.
- Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
-
Date lodged: Monday, 22 August 2022
-
Current Status:
Answered by Humza Yousaf on 20 September 2022
To ask the Scottish Government what discussions it has had with the Department of Health and Social Care regarding the procurement of Evusheld.
Answer
I refer the member to the answer to question S6W-10433 on 20 September 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers
- Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
-
Date lodged: Monday, 22 August 2022
-
Current Status:
Answered by Humza Yousaf on 20 September 2022
To ask the Scottish Government what work it is doing to ensure that pre-exposure prophylactics (PrEP) are available for immunocompromised patients, including people with myeloma, in relation to COVID-19.
Answer
I refer the member to the answer to question S6W-10433 on 20 September 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers